Cost‐savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real‐world cohort
| Autor: | Theodora Kanni, Evangelos J. Giamarellos-Bourboulis, N. Melachroinopoulos, M. Argyropoulou, Miltiades Kyprianou |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Cost-Benefit Analysis Anti-Inflammatory Agents MEDLINE Dermatology Severity of Illness Index Young Adult 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Cost Savings Internal medicine Severity of illness medicine Adalimumab Humans Hidradenitis suppurativa Young adult Retrospective Studies Greece Tumor Necrosis Factor-alpha business.industry Retrospective cohort study Odds ratio Middle Aged Symptom Flare Up medicine.disease Hidradenitis Suppurativa Hospitalization Cohort Female business Follow-Up Studies medicine.drug |
| Zdroj: | British Journal of Dermatology. 180:1161-1168 |
| ISSN: | 1365-2133 0007-0963 |
| DOI: | 10.1111/bjd.17151 |
| Popis: | Background The introduction of adalimumab in the management of hidradenitis suppurativa (HS) raises questions regarding the cost-efficacy of treatment. Objectives To explore cost-efficacy of treatment with anti-tumour necrosis factor (TNF) agents in a real-world cohort. Methods Patients with Hurley stage II and III HS with ≥ 1 year of follow-up and at least three visits per year from September 2003 to December 2016 were analysed. Patient visits were divided into two categories - visits for treatment with agents blocking TNF or visits for other therapies. The cost of exacerbations was calculated based on the cost of items provided in current price lists or by the national health insurance agency in cases of hospitalization. Effectiveness of anti-TNF agents was calculated by assessing containment of exacerbations. The primary study end point was the cost-savings achieved using anti-TNF agents. Results Overall, 1211 patient visits for 250 patients were analysed. Total containment of exacerbations was found in 25·1% of visits involving other therapies and in 63·4% of visits involving anti-TNF agents. The cost-savings per patient visit for patients receiving anti-TNF agents vs. other therapies was €178·92. The odds ratio for the total containment of exacerbations among patients with Hurley stage II and III was 4·86 and 6·03, respectively (P = 0·466). Treatment with anti-TNF agents was an independent variable affecting annual cost as shown by two-way analysis of variance. In Hurley stage III HS, mean annual cost was €8309·60 under other therapies compared with €3264·20 using anti-TNF agents (P = 0·004). Conclusions Treatment with anti-TNF agents achieves significant cost-benefit through containment of HS exacerbations. The efficacy of anti-TNF agents was similar for both disease stages. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text